Adverse effects: obesity or Cushing's Syndrome · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: obesity or Cushing's Syndrome compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: hypertension · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: hypertension compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse effects: acne · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: acne compared with oral steroids alone (low certainty).
1 finding from 1 review
Change in sensory score after one year · patients with nerve damage in leprosy
1 finding from 1 review
Proportion of ulnar nerves with sensory improvement after one year · patients with nerve damage in leprosy
It is very uncertain whether medial epicondylectomy plus oral steroids changes proportion of ulnar nerves with sensory improvement after one year compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in motor score after one year · patients with nerve damage in leprosy
1 finding from 1 review
Proportion of ulnar nerves with motor improvement after one year · patients with nerve damage in leprosy
It is very uncertain whether medial epicondylectomy plus oral steroids changes proportion of ulnar nerves with motor improvement after one year compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in sensory score after two years · patients with nerve damage in leprosy
1 finding from 1 review
Change in motor score after two years · patients with nerve damage in leprosy
1 finding from 1 review
Improvement in vertigo frequency · Ménière’s disease
Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).
2 findings from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
3 findings from 1 review
no estimate extracted
3 studies · 472 participants
Low
no estimate extracted
1 study · 20 participants
Very low
no estimate extracted
1 study · 18 participants
Very low
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether topical (intranasal) steroids changes adverse event: systemic corticosteroid side effects compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether topical (intranasal) steroids changes presence/persistence of OME (short‐term); assumed ICC = 0.5 compared with no treatment (very low certainty).
1 finding from 1 review
RR 0.72 [0.57, 0.91]
Studies not reported
Very low